Merck: acquisition of therapeutic antibody CN201 finalized

(CercleFinance.com) - Merck announced on Tuesday that it had completed the acquisition of the proprietary bispecific antibody CN201 from Curon Biopharmaceutical in order to strengthen its expertise in the treatment of lymphoma.


The US pharmaceutical giant points out that CN201 is currently in Phase 1 and Phase 1b/2 clinical trials in relapsed or refractory non-Hodgkin's lymphoma and relapsed or refractory acute lymphoblastic leukemia (ALL).

According to Merck, preliminary data have demonstrated the efficacy and safety of CN201 in relapsed or refractory B-cell hematological malignancies.

Under the terms of the acquisition, Merck expects to recognize a pre-tax charge of $750 million, or $0.28 per share, in its third-quarter financial statements.

Copyright (c) 2024 CercleFinance.com. All rights reserved.